Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
October 10, 2008
 
Industry Categories  
News by Country  
News by MSA  
Today's News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for October 10, 2006 Subscribe to this News Feed    Subscribe to this Podcast Feed
 

Tamiflu Abundant but Compliance Scarce: Treatment Potential Unattainable Without Adherence

Even with the increased availability of antiviral medications such as Tamiflu, health care officials advise that patients remember that adherence to a drug regimen is crucial to the outcome of treatment plans. Ensuring that medications are taken properly, completely and specifically as directed by a physician or pharmacist are the key to successfully fighting off illnesses such as influenza. For children, compliance can be improved to over 90% with the addition of flavoring such as FLAVORx.

Bethesda, MD (PRWEB) October 10, 2006 -- Roche recently announced that for the 2006/2007 flu season, pharmacies can expect to double their stock of Tamiflu in comparison to last year. This increased production has pharmacists, healthcare practitioners and patients alike feeling assured that they will be able to receive the medication needed to treat flu symptoms. However, health care officials and researchers warn that if patients fail to adhere to medication regimens, they may in fact be contributing to failed treatment programs (deterioration of health, use of extra drugs, additional consultations), higher costs of care and most severe, the development of drug resistant organisms that cause further the spread of disease. This is of extreme concern for pediatric patients who are not only 2-3 times more likely to contract the flu, but also only 50% compliant when it comes to taking medications.

tamiflu.jpg

Children are at an increased risk for influenza-related hospitalizations and much more likely to spread infection to other children, family members and even out-of-home caregivers. According to the National Institute of Allergy and Infectious Disease (NIAID), "because schools are an excellent place for flu viruses to attack and spread, families with school-age children have more infections than other families with an average of 1/3 of the family members infected each year."

A key contributor to non-adherence in children is palatability. Bitter taste or foul smell can make a child extremely resistant to swallowing a medication. Studies have shown that compliance with therapy is directly related to palatability and, for certain medications, the only motivation for a child to take a medication may be taste. For children, swallowing medications can be particularly problematic because pills are difficult to swallow and liquid suspensions have direct contact with their sensitive taste buds.

Medications like Tamiflu are prepared in suspension for children and infants who have difficulty swallowing pills but are found to be particularly bitter. Safe, effective flavoring systems such as FLAVORx are able to mask the existing taste of the medication and convert the suspension to a flavor of the patient’s choice. FLAVORx’s 42 flavors are FDA-approved, non-allergenic, sugar-free, dye-free and phosphate free. In over 40 million flavorings, the company has yet to report any incidence of adverse reaction, allergy or changes in efficacy. Each medication’s flavoring ‘recipe’ or formulary must undergo rigorous safety and stability testing prior to its release to patients. Studies show that in children compliance improves to over 90% with the addition of FLAVORx to medications. Behavior such as this enhances treatment outcomes by eliminating symptoms, improving health and decreasing the likelihood of infectious spread.

According to Kenny Kramm, President and CEO of FLAVORx, Inc, “Medications like Tamiflu and other antivirals are extremely bitter, especially for sensitive young palates. Until people actually taste or smell the medications that they’re forcing their children and patients to take, they don’t realize how physically intolerable medications can be.”

Taking a medication improperly or not completing a full regimen leads to a reduction in symptoms, but does not lead to eradication of an illness. While seemingly inconsequential, not fully ridding the body of infection could lead to children and adults returning to school or the workplace symptom-free but still as viral carriers. The virus will not be completely contained and infection will continue to spread, likely with a more virulent strain that has become partially resistant to a drug’s effects, and rendering the original drug virtually ineffective.

For more information on FLAVORx, please visit www.flavorx.com or contact Teresa Chen at 800.884.5771 extension 234.

# # #

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1Mb3ZlLVRoaXItRmFsdS1JbnNlLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Teresa Chen
FLAVORX, INC.
240.223.0953
Email us Here
ATTACHED FILES

Adding flavoring can improve medicinal compliance to over 90% in children.

FLAVORx Inc.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright